Search results for "Highlights"
Program directs stable diabetes patients from endocrinology back to primary care
One academic health system developed a program to “graduate” patients out of endocrinology visits for their diabetes. Criteria included HbA1c level less than 8.0%, blood pressure less than 140/90 mm Hg, no tobacco use, and use of statins and aspirin if needed.
https://diabetes.acponline.org/archives/2022/09/16/1.htm
16 Sep 2022
Rates of hypoglycemic, hyperglycemic crises high in patients with diabetes and ESKD
The results of a retrospective study of U.S. data in patients with both diabetes and end-stage kidney disease (ESKD) indicate that current glycemic monitoring and treatment in this population are suboptimal, the authors said.
https://diabetes.acponline.org/archives/2021/11/12/3.htm
12 Nov 2021
Antidepressant adherence linked to lower risk of advanced complications of diabetes
In patients with diabetes and depression in Taiwan, regular use of an antidepressant was associated with a 0.92-fold decreased risk of macrovascular complications and a 0.86-fold decreased risk of all-cause mortality compared with poor adherence.
https://diabetes.acponline.org/archives/2021/08/13/2.htm
13 Aug 2021
No differences seen in outcomes with one-step vs. two-step gestational diabetes screening
The one-step screening process, which used a two-hour fasting glucose tolerance test, found more cases of gestational diabetes in a randomized trial, but perinatal and maternal complications did not differ.
https://diabetes.acponline.org/archives/2021/03/12/2.htm
12 Mar 2021
DPP-4 inhibitors associated with risk of cholecystitis, meta-analysis finds
Patients with type 2 diabetes who were randomized to receive dipeptidyl peptidase-4 (DPP-4) inhibitors had higher rates of gallbladder disease than those who got placebo or nonincretin drugs, but no difference in risk of cholelithiasis or biliary diseases.
https://diabetes.acponline.org/archives/2022/07/08/1.htm
8 Jul 2022
Physician-patient discussions may decrease unnecessary self-monitoring of blood glucose levels
In a cross-sectional survey at an Ohio health system, 67% of respondents with non-insulin-controlled type 2 diabetes said they monitored their blood glucose levels because their physician had asked them to, and 50% said they would stop if given permission.
https://diabetes.acponline.org/archives/2021/09/10/2.htm
10 Sep 2021
Choice of SGLT-2 inhibitors, GLP-1 receptor agonists should be based on individual risk
A meta-analysis comparing sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists found differing effects, including that the SGLT-2 inhibitors affected heart failure outcomes while GLP-1 receptor agonists reduced stroke risk.
https://diabetes.acponline.org/archives/2021/02/12/3.htm
12 Feb 2021
SGLT-2 inhibitors associated with increased risk for diabetic ketoacidosis
A cohort study found a threefold increase in the risk for diabetic ketoacidosis with sodium-glucose cotransporter-2 (SGLT-2) inhibitors compared to dipeptidyl peptidase-4 (DPP-4) inhibitors, with possible variation by severity or duration of diabetes.
https://diabetes.acponline.org/archives/2020/08/14/2.htm
14 Aug 2020
Statins associated with progression of diabetes
A retrospective study of veterans with diabetes found that those who started statin therapy were more likely to meet criteria for diabetes progression, such as initiation of insulin or an additional antihyperglycemic drug class, over time.
https://diabetes.acponline.org/archives/2021/10/08/3.htm
8 Oct 2021
GLP-1 receptor agonists improved cardiovascular, kidney outcomes in type 2 diabetes
In a systematic review and meta-analysis of eight randomized controlled trials, glucagon-like peptide-1 (GLP-1) receptor agonists reduced major adverse cardiovascular events by 14%, all-cause mortality by 12%, hospital admission for heart failure by 11%, and a composite kidney outcome by 21%, with no increase in safety outcomes.
https://diabetes.acponline.org/archives/2021/09/10/3.htm
10 Sep 2021